Head and neck diseases

Summary

The Head and neck research group, as part of its line of cancer research, studies new therapeutic targets and predictive biomarkers of response to chemotherapy, radiotherapy and immunotherapy, the role of the human papilloma virus (HPV) and the differential management of HPV+ tumours, transoral treatment of laryngeal cancer with CO2 laser and robotic surgery, reconstructive surgery and pharyngeal rehabilitation of laryngectomised patients

406 Publications

Strategic lines

Recurrent respiratory papillomatosis. etiologic, clinic and treatment aspects, vaccine effects on the evolution and control of this desease.
The new era of ear surgery : endoscopic ear surgery, safe techniques and results.
Impacts of body composition in head and neck cancer
New techniques for the surgical management of hereditary hemorragic telangiectasia (rendu-osler-weber disease)
The effects of biologic treatments in chronic rhinosinusitis with polyposis.
Radiomics and head and neck tumors
The implementation of artificial intelligence in the diagnosis and management of head and neck tumors
CT evaluation of sinonasal anatomy to improve the results and safeness of functional endoscopic sinonasal surgery
Robotic surgery implementation and results in head and nceck cancer
HPV and head and neck cancer

Selected Publications

Lorenzo Sanz,L;Lopez Cerda,M;da Silva Diz,V;Artés,MH;Llop,S;Penin,RM;Bermejo,JO et al, Cancer cell plasticity defines response to immunotherapy in cutaneous squamous cell carcinoma, Nat Commun, 2024;15(1):5352-5352, doi:10.1038/s41467-024-49718-8
Lopez Cerda,M;Lorenzo Sanz,L;da Silva Diz,V;Llop,S;Penin,RM;Bermejo,JO;Haas,RD et al, IGF1R signaling induces epithelial-mesenchymal plasticity via ITGAV in cutaneous carcinoma, J. Exp. Clin. Cancer Res., 2024;43(1):211-211, doi:10.1186/s13046-024-03119-3
Cruzado,JM;Sola,A;Pato,ML;Manonelles,A;Varela,C;Setién,FE;Quero Dotor,C et al, Severe ischemia-reperfusion injury induces epigenetic inactivation of LHX1 in kidney progenitor cells after kidney transplantation., Am. J. Transplant., 2024;doi:10.1016/j.ajt.2024.11.003
Baliga,S;Abou Foul,AK;Parente,P;Szturz,P;Thariat,J;Shreenivas,A;Nankivell,P et al, Essential data variables for a minimum dataset for head and neck cancer trials and clinical research: HNCIG consensus recommendations and database, Eur J Cancer, 2024;203114038-114038, doi:10.1016/j.ejca.2024.114038
Valenzuela,LM;Gómez Preciado,F;Guiteras,J;Pampols,PA;Gomà,M;Fulladosa,X;Cruzado,JM et al, Immune checkpoint inhibitors induce acute interstitial nephritis in mice with increased urinary MCP1 and PD-1 glomerular expression, J Transl Med, 2024;22(1):421-421, doi:10.1186/s12967-024-05177-9

Selected Projects

20ACL093. A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 OR PLACEBO IN COMBINATION WITH PEMBROLIZUMAB FOR FIRST-LINE TREATMENT OF PD-L1 POSITIVE RECURRENT/METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA. GlaxoSmithKline Research & Development Limited;GlaxoSmithKline, S.A.. Budget: 236.335,84€. 2024. PI: Plana Serrahima, María.
2023-491-1. PHASE 1-2 STUDY INVESTIGATING SAFETY, TOLERABILITY, PHARMACOKINETICS AND PRELIMINARY ANTITUMOR ACTIVITY OF ANTI-TIM-3 MONOCLONAL ANTIBODY BGB-A425 IN COMBINATION WITH ANTI-PD-1 MONOCLONAL ANTIBODY TISLELIZUMAB IN PATIENTS WITH ADVANCED SOLID TUMORS. BEIGENE SWITZERLAND GMBH. Budget: 233.370€. 2023- . PI: OLIVA BERNAL, MARC.
20ACL112. Estudio clínico de fase 2, aleatorizado, abierto y de tres grupos para evaluar la seguridad y la eficacia de lenvatinib (E7080/MK-7902) en combinación con pembrolizumab (MK-3475) frente a la quimioterapia de referencia y lenvatinib en monoterapia en parti. MERCK SHARP & DOHME ESPAÑA S.A. Budget: 215.055€. 2020- . PI: Taberna Sanz, Miren.2023-351-1. ENSAYO DE FASE I, ABIERTO, DE ESCALADO DE DOSIS DE BI 1831169 EN MONOTERAPIA Y EN COMBINACIÓN CON EZABENLIMAB EN PACIENTES CON TUMORES SÓLIDOS AVANZADOS O METASTÁSICOS. Boehringer Ingelheim España, S.A. Budget: 201.126€. 2023- . PI: OLIVA BERNAL, MARC.
TTCC. MoleculaR profiling and ImmunophEnotyping as preDictors of outcomE in non-metastatic SalIvary Gland carciNomas (REDESIGN). Grupo Español de Tratamiento de Tumores de Cabeza y Cuello (TTCC). Budget: 80.000€. 2022-2025. PI: OLIVA BERNAL, MARC.

More Information